The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2025 | Elucidating optimal first-line immunotherapy combinations in HCC
Lorenza Rimassa, MD, Hunimed University, Milan, Italy, discusses the current state of immunotherapy combinations for the first-line treatment of patients with advanced hepatocellular carcinoma (HCC). Based on the TRIPLET-HCC trial (NCT05665348), which produced negative results, double immunotherapy combinations remain the standard of care. However, ongoing trials may still provide new therapeutic options in the near future. This interview took place at the European Society for Medical Oncology (ESMO) 2025 Congress in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So, based on the trial presented at ESMO 2025, no new immunotherapy combinations will be available for the first-line treatment of patients with advanced HCC because the trials presented here in this setting are all negative. So, based on the data that we have so far, double immunotherapy combinations remain the standard of care. Of course, there are other ongoing trials and we will see in the near future if they will be positive and so if we will be able to provide our patients with new therapeutic options...
So, based on the trial presented at ESMO 2025, no new immunotherapy combinations will be available for the first-line treatment of patients with advanced HCC because the trials presented here in this setting are all negative. So, based on the data that we have so far, double immunotherapy combinations remain the standard of care. Of course, there are other ongoing trials and we will see in the near future if they will be positive and so if we will be able to provide our patients with new therapeutic options.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
